BiVictriX Therapeutics Statistics
Total Valuation
BiVictriX Therapeutics has a market cap or net worth of GBP 8.25 million. The enterprise value is 6.77 million.
Market Cap | 8.25M |
Enterprise Value | 6.77M |
Important Dates
The next estimated earnings date is Tuesday, September 17, 2024.
Earnings Date | Sep 17, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
BiVictriX Therapeutics has 82.53 million shares outstanding. The number of shares has increased by 14.81% in one year.
Shares Outstanding | 82.53M |
Shares Change (YoY) | +14.81% |
Shares Change (QoQ) | -8.25% |
Owned by Insiders (%) | 14.44% |
Owned by Institutions (%) | 37.81% |
Float | 47.59M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | 3.58 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -2.53 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -3.19 |
Financial Position
The company has a current ratio of 4.40, with a Debt / Equity ratio of 8.81.
Current Ratio | 4.40 |
Quick Ratio | 4.40 |
Debt / Equity | 8.81 |
Debt / EBITDA | n/a |
Debt / FCF | -0.10 |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -103.99% and return on invested capital (ROIC) is -70.51%.
Return on Equity (ROE) | -103.99% |
Return on Assets (ROA) | -62.99% |
Return on Capital (ROIC) | -70.51% |
Revenue Per Employee | n/a |
Profits Per Employee | -157,118 |
Employee Count | 17 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.57% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -28.57% |
50-Day Moving Average | 10.99 |
200-Day Moving Average | 11.32 |
Relative Strength Index (RSI) | 59.32 |
Average Volume (20 Days) | 584,670 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -3.24M |
Pretax Income | -3.21M |
Net Income | -2.67M |
EBITDA | -3.17M |
EBIT | -3.24M |
Earnings Per Share (EPS) | -0.04 |
Balance Sheet
The company has 1.69 million in cash and 203,000 in debt, giving a net cash position of 1.49 million or 0.02 per share.
Cash & Cash Equivalents | 1.69M |
Total Debt | 203,000 |
Net Cash | 1.49M |
Net Cash Per Share | 0.02 |
Equity (Book Value) | 2.31M |
Book Value Per Share | 0.03 |
Working Capital | 2.00M |
Cash Flow
In the last 12 months, operating cash flow was -2.27 million and capital expenditures 151,000, giving a free cash flow of -2.12 million.
Operating Cash Flow | -2.27M |
Capital Expenditures | 151,000 |
Free Cash Flow | -2.12M |
FCF Per Share | -0.03 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
BiVictriX Therapeutics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -14.81% |
Shareholder Yield | -14.81% |
Earnings Yield | -35.21% |
FCF Yield | -25.71% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |